Oxford, UK – 29 November 2013. Oxford Gene Technology (OGT), provider of innovative genetics research and biomarker solutions to advance molecular medicine, has produced a free whitepaper titled ‘The importance of enrichment assay choice and optimisation for confident variant detection.’ The paper investigates the main strategies employed to optimise target enrichment for next generation sequencing (NGS) assays, assisting researchers to make informed decisions when designing studies.
The choice of target enrichment methodology can have a dramatic effect on the ability to confidently call each variant with no false negatives or positives. The whitepaper by OGT examines the impact of enrichment assay choice, comparing and contrasting hybridisation and amplicon approaches while considering factors such as target size, accuracy, cost and speed. The paper also addresses the potential sources of bias and error in enrichment assays, giving the reader a truly comprehensive overview of the subject.
Researchers can overcome the challenge of enrichment assay design with the use of an expert service provider. OGT’s Genefficiency NGS Services encompass an Expert Bait Design workflow that significantly improves the uniformity of target sequence enrichment, increasing sensitivity and accuracy of variant detection across the entire region. In addition, all results are provided in the unique Genefficiency NGS Variant Analysis Report that provides the freedom to interrogate the fully annotated data, without the need for local bioinformatics resource.
Download the free whitepaper.
To find out more about OGT’s Genefficiency Sequencing Services, visit the OGT website or contact us at firstname.lastname@example.org.
About Oxford Gene Technology
Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative genetics research and biomarker solutions to advance molecular medicine. The company has two trading businesses: Genomics comprises of CytoSure™ cytogenetics array, labelling and interpretation software products and services for the detection of chromosomal abnormalities, and Genefficiency™ Genomic Services, a unique combination of platforms, expertise and processing capabilities to deliver rapid, relevant genomic data. The Biomarkers business utilises proprietary next generation technologies to build a rich patent-protected portfolio of promising biomarkers for early stage cancer detection including advanced programmes in colorectal and prostate cancer plus the autoimmune disease systemic lupus erythematosus.
CytoSure™ and Genefficiency™ NGS browser/report: For Research Use Only; Not for Use in Diagnostic Procedures
CytoSure: This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.
For further information, please contact:
Oxford Gene Technology, Begbroke Science Park
Begbroke Hill, Woodstock Road, Begbroke, Oxfordshire, OX5 1PF, U.K.
T: +44 (0) 1865 856826 ; F: +44 (0) 1865 848684
E: email@example.com; W: www.ogt.com ; Twitter: @OxfordGeneTech
Oxford Gene Technology - OGT
Stephen Archibald: Director of Communications
t: +44 (0)1865 856828